ID   BEL-7404
AC   CVCL_6568
SY   Bel-7404; BEL 7404; Bel 7404; BEL7404; Bel7404; 7404
DR   BTO; BTO:0005814
DR   ChEMBL-Cells; CHEMBL3307908
DR   ChEMBL-Targets; CHEMBL614280
DR   GEO; GSM743502
DR   GEO; GSM936755
DR   GEO; GSM1374401
DR   PubChem_Cell_line; CVCL_6568
DR   Wikidata; Q54795973
RX   DOI=10.1007/978-4-431-68349-0_4;
RX   PubMed=6154311;
RX   PubMed=6275024;
RX   PubMed=11774261;
RX   PubMed=23505090;
RX   PubMed=28807831;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=28807831). Originally thought to originate from a 69 year old male patient with a hepatocellular carcinoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00550.
CC   Population: African American.
CC   Doubling time: 26 hours (PubMed=6154311).
CC   Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3131C0001000700064). It was the sole source for the STR profile of this entry.
CC   Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002.
ST   Source(s): CCRID
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D13S317: 12,13.3
ST   D16S539: 9,10
ST   D18S51: 16
ST   D19S433: 13,14
ST   D21S11: 27,28
ST   D2S1338: 17
ST   D3S1358: 18
ST   D5S818: 11,12
ST   D7S820: 8,12
ST   D8S1179: 12
ST   FGA: 21
ST   TH01: 7
ST   TPOX: 8,12
ST   vWA: 16,18
DI   NCIt; C27677; Human papillomavirus-related cervical adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0030 ! HeLa
SX   Female
AG   30Y6M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 27
//
RX   DOI=10.1007/978-4-431-68349-0_4;
RA   Alexander J.J.;
RT   "Human hepatoma cell lines.";
RL   (In) Neoplasms of the liver; Okuda K., Ishak K.G. (eds.); pp.47-56; Springer; Tokyo (1987).
//
RX   PubMed=6154311; DOI=10.1360/ya1980-23-2-236;
RA   Chen R.-M., Zhu D.-H., Ye X.-Z., Shen D.-W., Lu R.-H.;
RT   "Establishment of three human liver carcinoma cell lines and some of
RT   their biological characteristics in vitro.";
RL   Sci. Sin. 23:236-247(1980).
//
RX   PubMed=6275024; DOI=10.1099/0022-1317-57-1-95;
RA   Koshy R., Maupas P., Muller R., Hofschneider P.H.;
RT   "Detection of hepatitis B virus-specific DNA in the genomes of human
RT   hepatocellular carcinoma and liver cirrhosis tissues.";
RL   J. Gen. Virol. 57:95-102(1981).
//
RX   PubMed=11774261; DOI=10.1002/ijc.1597;
RA   Zhang R., Wang X., Guo L., Xie H.;
RT   "Growth inhibition of BEL-7404 human hepatoma cells by expression of
RT   mutant telomerase reverse transcriptase.";
RL   Int. J. Cancer 97:173-179(2002).
//
RX   PubMed=23505090; DOI=10.1002/hep.26402;
RA   Wang K., Lim H.Y., Shi S., Lee J., Deng S.-B., Xie T., Zhu Z.,
RA   Wang Y.-L., Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K.,
RA   Xu J.-C.;
RT   "Genomic landscape of copy number aberrations enables the
RT   identification of oncogenic drivers in hepatocellular carcinoma.";
RL   Hepatology 58:706-717(2013).
//
RX   PubMed=28807831; DOI=10.1016/j.jhep.2017.08.002;
RA   Rebouissou S., Zucman-Rossi J., Moreau R., Qiu Z.-X., Hui L.-J.;
RT   "Note of caution: contaminations of hepatocellular cell lines.";
RL   J. Hepatol. 67:896-897(2017).
//